Cefepime-Induced Encephalopathy in a Tertiary Medical Center in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Cefepime is a widely used fourth-generation cephalosporin. It is commonly used as a first-line antibiotic to treat various infectious diseases such as hospital- acquired pneumonia, urinary tract infections, and bacterial meningitis. The primary outcome of this study was the development of cefepime-induced encephalopathy (CIE) at a tertiary medical center in Korea. We also aimed to describe the clinical features of CIE. Methods We enrolled 1,793 consecutive patients treated with cefepime. The CIE group included 44 patients who experienced altered consciousness after receiving cefepime without any other obvious cause and showed full recovery after stopping cefepime. This study collected demographic data, laboratory findings, and clinical data including the cause of infection, duration for onset of altered consciousness, duration of cefepime treatment, dosage of cefepime, duration of recovering consciousness after stopping cefepime, sequelae after encephalopathy, and electroencephalography data. Results Forty-four (2.5%) patients were included in the CIE group. The age was significantly higher in the CIE group than in the control group (71.2±10.8 years vs. 64.7±16.1 years, mean± standard deviation; p=0.007), and females constituted a significantly large proportion in the CIE group (27 of 44, 61.4%). The CIE group had higher blood urea nitrogen (34.7±22.6 mg/dL vs. 23.0±17.5 mg/dL, p<0.001) and creatinine (2.2±2.5 mg/dL vs. 1.1±1.3 mg/dL, p<0.001), and lower estimated glomerular filtration rate (eGFR) (56.3±46.0 mL/min/1.73 mm2 vs. 98.8±66.3 mL/min/1.73 mm2, p<0.001). Multivariate analysis showed that only eGFR was significantly related to CIE. Conclusions The incidence of CIE was 2.5% in this study. It is essential to consider the possibility of CIE occurring, especially in patients with lower values of eGFR and dialysis.
Abstract
Background and Purpose Cefepime is a widely used fourth-generation cephalosporin. It is commonly used as a first-line antibiotic to treat various infectious diseases such as hospital- acquired pneumonia, urinary tract infections, and bacterial meningitis. The primary outcome of this study was the development of cefepime-induced encephalopathy (CIE) at a tertiary medical center in Korea. We also aimed to describe the clinical features of CIE. Methods We enrolled 1,793 consecutive patients treated with cefepime. The CIE group included 44 patients who experienced altered consciousness after receiving cefepime without any other obvious cause and showed full recovery after stopping cefepime. This study collected demographic data, laboratory findings, and clinical data including the cause of infection, duration for onset of altered consciousness, duration of cefepime treatment, dosage of cefepime, duration of recovering consciousness after stopping cefepime, sequelae after encephalopathy, and electroencephalography data. Results Forty-four (2.5%) patients were included in the CIE group. The age was significantly higher in the CIE group than in the control group (71.2±10.8 years vs. 64.7±16.1 years, mean± standard deviation; p=0.007), and females constituted a significantly large proportion in the CIE group (27 of 44, 61.4%). The CIE group had higher blood urea nitrogen (34.7±22.6 mg/dL vs. 23.0±17.5 mg/dL, p<0.001) and creatinine (2.2±2.5 mg/dL vs. 1.1±1.3 mg/dL, p<0.001), and lower estimated glomerular filtration rate (eGFR) (56.3±46.0 mL/min/1.73 mm2 vs. 98.8±66.3 mL/min/1.73 mm2, p<0.001). Multivariate analysis showed that only eGFR was significantly related to CIE. Conclusions The incidence of CIE was 2.5% in this study. It is essential to consider the possibility of CIE occurring, especially in patients with lower values of eGFR and dialysis.
참고문헌 (16)
- Martin SI, "Beta-lactam antibiotics : newer formulations and newer agents", Infect Dis Clin North Am, 18, pp.603~619 (2004)
- Appa AA, "Characterizing cefepime neurotoxicity : a systematic review", Open Forum Infect Dis, 4, pp.ofx170~ (2017)[DOI]
- Bhattacharyya S, "Antibiotic-associated encephalopathy", Neurology, 86, pp.963~971 (2016)
- Lin CJ, "Cefepime-related encephalopathy in peritoneal dialysis patients", J Chin Med Assoc, 74, pp.87~90 (2011)
- Dixit S, "Status epilepticus associated with cefepime", Neurology, 54, pp.2153~2155 (2000)
- Thabet F, "Cefepime-induced nonconvulsive status epilepticus : case report and review", Neurocrit Care, 10, pp.347~351 (2009)
- Naeije G, "Continuous epileptiform discharges in patients treated with cefepime or meropenem", Arch Neurol, 68, pp.1303~1307 (2011)
- Kang JK, "Neurotoxicity by cefepime : case-control study", J Neurocrit Care, 7, pp.104~110 (2014)
- Fugate JE, "Cefepime neurotoxicity in the intensive care unit : a cause of severe, underappreciated encephalopathy", Crit Care, 17, pp.R264~ (2013)
- Mine Y, "In vitro antibacterial activity of FK037, a novel parenteral broadspectrum cephalosporin", J Antibiot(Tokyo), 46, pp.71~87 (1993)
- Sugimoto M, "Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins", Neuropharmacology, 45, pp.304~314 (2003)
- Fishbain JT, "Cerebral manifestations of cefepime toxicity in a dialysis patient", Neurology, 55, pp.1756~1757 (2000)
- Jallon P, "Severe but reversible encephalopathy associated with cefepime", Neurophysiol Clin, 30, pp.383~386 (2000)
- Coelho FM, "Cefepime-induced encephalopathy in patient without renal failure", Einstein (Sao Paulo), 8, pp.358~360 (2010)
- Johnson E, "Cefepime-associated SIRPIDs in a patient with normal renal function", Neurohospitalist, 6, pp.167~169 (2016)
- Schlidt K, "Cefepime-induced neurotoxicity : five cases reported in a single institution", Cureus, 10, pp.e3666~ (2018)